Connecticut 500 W Putnam Ave Ste 435 Greenwich, CT 06830





## VIMIZIM® (elosulfase alfa)

Provider \_

\_\_\_\_\_\_ Phone \_\_\_\_\_\_ Fax \_\_\_

ORDER FORM

Mission	Medical	

Date: \_\_\_\_\_

Name	PATIENT INFORMATION										
Physician Name*:	Name:	I					SEX: M □	F 🗆			
PHYSICIAN INFORMATION  Practice Name:  Address:   Office Contact Name:   Office Contact #:  REFERRAL STATUS    New Referral   Referral Renewal   Medication/Order Change   Benefits Verification Only   Discontinuation Order  VIMIZIM*:   VIMIZIM is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). F76.210    DOSAGE AND ADMINISTRATION:   Recommended Dose   Pre-treatment with antibistamines with or without antipyretics is recommended 20 to 60 minutes prior to the start of the infusion.   PRE-MEDICATION   Tylenol PO 650mg (1000 MG other   10 V 10 PO   Benadyl 50 mg   10 FO   10 V 10 PO   Benadyl 50 mg   10 FO   10 V 10 PO   10 V 10 PO   10 V 10	□NKDA Allergies:	Thone.				ight lbs/kg:					
Physician Name:											
Address:   Office Contact Name:   Office Contact &:   Phone:   Fax:   Email (for updates):											
New Referral   Referral Renewal   Medication/Order Change   Benefits Verification Only   Discontinuation Order	•		Office								
New Referral   Referral Renewal   Medication/Order Change   Benefits Verification Only   Discontinuation Order				il (for updates):							
New Referral   Referral Renewal   Medication/Order Change   Benefits Verification Only   Discontinuation Order			RFFFRF	RAL STATUS							
VIMIZIM®:  VIMIZIM is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), E76.210  DOSAGE AND ADMINISTRATION:  Recommended Dose Pre-treatment with antihistamines with or without antipyretics is recommended at 0 to 60 minutes prior to the start of the infusion.  PRE-MEDICATION  Tylenol PO 650mg   1000 MG   other											
DOSAGE AND ADMINISTRATION: Recommended Dose Pre-treatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes prior to the start of the infusion.  PRE-MEDICATION    Tylenol PO 650mg   Cloud MC   Cother				, , , , , , , , , , , , , , , , , , ,		) <b>57</b> 6 242					
PRE-MEDICATION    Tylenol PO 650mg   1000 MG   other	□ VIMIZIM is indicated for patients with Mucopol	lysaccha	aridosis	type IVA (MPS IVA;	Morquio A syndrom	ie). E/6.210					
Tylenol PO 650mg   1000 MG   100 her	Recommended Dose Pre-treatment with antihistamines with or without antipyretics is			PATIENT WEIG	GHT s.						
Solumedrol 125mg IV Other	PRE-MEDICATION				•						
Benadryl 25 mg	□ Tylenol PO 650mg □1000 MG □other			DOSAGE							
Benadryl 50 mg											
Medication	□ Benadryl □25mg □50mg □other □ IV	□PO		□ Other							
MARNINGS AND PRECAUTIONS https://www.wimizim.com/wp-content/uploads/2018/02/ Prescribing-Information.pdf  WARNING: RISK OF ANAPHYLAXI Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions. Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment. Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms occur. Patients with acute respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  **CORDERING PROVIDER**  WARNINGS AND PRECAUTIONS https://www.wimizim.com/wp-content/uploads/2018/02/ Prescribing-Information.  Cother  **X weeks  **Other  **Dither**  REQUIRED DOCUMENTATION CHECKLIST:  — Patient Demographics  — Insurance Card/Information  — Recent Progres notes addressing VIMIZIM in note  — Recent labs to include CBC, CMP, and please send any other recent labs.  — Other  Other	□ Benadryl 50 mg □ or PO			FREQUENCY							
WARNINGS AND PRECAUTIONS https://www.winizim.com/wp-content/uploads/2018/02/ Prescribing-information.pdf  WARNING: RISK OF ANAPHYLAXI  Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms occur. Patients with acute respiratory compromise due to hypersensitivity reactions, and require additional monitoring.    X	☐ Medication DoseRoute										
WARNINGS AND PRECAUTIONS https://www.vimizim.com/wp-content/uploads/2018/02/ Prescribing-Information.pdf  WARNING: RISK OF ANAPHYLAXI  Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate are should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  CORDERING PROVIDER											
https://www.vimizim.com/wp-content/uploads/2018/02/ Prescribing-Information.pdf  WARNING: RISK OF ANAPHYLAXI  Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  **ORDERING PROVIDER**  **REQUIRED DOCUMENTATION CHECKLIST:  Patient Demographics  **Insurance Card/Information    Insurance Card/Information   Insurance Card/Information   Recent labs to include CBC, CMP, and please send any other recent labs.  — Other  **Other**  Other**	(duct)		(Oliver)			_ weeks					
Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  REQUIRED DOCUMENTATION CHECKLIST:  — Patient Demographics  — Insurance Card/Information  — Recent labs to include CBC, CMP, and please send any other recent labs.  — Other  ORDERING PROVIDER	https://www.vimizim.com/wp-content/uploads/2018/02/			Other			<del></del>				
during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  REQUIRED DOCUMENTATION CHECKLIST:  — Patient Demographics  Insurance Card/Information  — Recent Progres notes addressing VIMIZIM in note  — Recent labs to include CBC, CMP, and please send any other recent labs.  — Other  ORDERING PROVIDER	WARNING: RISK OF ANAPHYLAXI										
flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Patient Demographics  Insurance Card/Information  Recent Progres notes addressing VIMIZIM in note  Recent labs to include CBC, CMP, and please send any other recent labs.  Other  Other	during VIMIZIM (elosulfase alfa) infusions.	fe-threatening anaphylactic reactions have occurred in some patients uring VIMIZIM (elosulfase alfa) infusions.			REQUIRED DOCUMENTATION CHECKLIST:						
vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment.  Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Insurance Card/Information  Recent Progres notes addressing VIMIZIM in note  Recent labs to include CBC, CMP, and please send any other recent labs.  ———————————————————————————————————	flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur			Patient Demographics							
Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Closely observe patients during and after VIMIZIM (elosulfase alfa)  Recent labs to include CBC, CMP, and please send any other recent labs.  ———————————————————————————————————											
administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Recent labs to include CBC, CMP, and please send any other recent labs.  ———————————————————————————————————				Recent Progr	es notes addressing	<b>VIMIZIM</b> in	note				
medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Other  ORDERING PROVIDER				Recent labs t	o include CBC, CMI	P, and pleas	e send any ot	her			
illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.  Other  ORDERING PROVIDER	of the signs and symptoms of anaphylaxis and have them seek immediate			recent labs.							
compromise due to hypersensitivity reactions, and require additional monitoring.  ORDERING PROVIDER				Other							
	compromise due to hypersensitivity reactions, and require a			cure.							
Signature X Date NPI	ORDERING PROVIDER										
····	Signature X	Date	N	IPI							